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PhosphorylationDownregulation of multiple cell cycle-regulatory molecules is a dominant event in TGF-β1-mediated growth in-
hibition of human carcinoma cells. It is known that KLF10mimics the anti-proliferative and apoptotic effects that
TGF-β1 has on epithelial cell growth and the growth of various tumor cells; based on these ﬁndings it is consid-
ered as a tumor suppressor. KLF10 protein expression is tightly associated with cell cycle-dependent events.
However, the regulatory mechanism and its biological meaning have not been identiﬁed. In this study, we
have demonstrated that KLF10 is a substrate of CDK2/cyclin E and can be phosphorylated. We also have shown
that KLF10 efﬁciently binds to CDK2, while binding much less to CDK4, and displaying no binding to Cdk6.
Using mass spectrometry, site direct mutagenesis, in vitro kinase assays and depletion assays, we have
established that CDK2 phosphorylates Ser206, which subsequently affects the steady state level of KLF10 in
cells. Our studies have also proved that CDK2 up-regulates the protein level of KLF10 through reducing its asso-
ciation with SIAH1, a KLF10 E3-ubiqutin ligase involved in proteasomal degradation. Taken all together, these
ﬁndings indicate that CDK2-dependent phosphorylation regulates KLF10 stability and that this affects the role
of KLF10 in cell.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
TGF-β1 has been generally observed to possess dual but opposite
functions; it acts as a growth factor in mesenchymal cells and in pro-
gressivemalignant cells, but plays an inhibitory role during the cell pro-
liferation of most epithelial cells. Thus the concept has been accepted
that TGF-β1 can function either as tumor suppressor during the early
stages of carcinomadevelopment or as a factor that provides growth ad-
vantages during the later stages of cancer progression [1]. Themost crit-
ical effect of TGF-β on target cells is suppression of proliferation. Its
growth inhibitory function is based on the protein's ability to suppress
the expression and function of c-Myc and various cyclin-dependent ki-
nases (CDKs) and to enhance expression of the CDK inhibitors [2–7]. In-
creased levels of these inhibitors result in a major inhibition of CDK
activity that has been associated with an effect on early G1 phase pro-
gression; this inhibition locks the cell cycle prior to the G1 restriction
point.Medicine, College of Medical
Wu-Hsing Street, Taipei City,
.Additional signaling molecules have been reported to be critical in
terms of the anti-proliferative response to TGF-β, but their pathways
and general importance have not been established. KLF10was originally
named as a TGF-β inducible early gene-1 that mimics the anti-
proliferative effect of TGF-β in various carcinoma cells. The transcrip-
tional upregulatory function of KLF10 has been described for a variety
of cytokines and in many diseases. Jiang et al. indicated that lentivirus-
mediated overexpression of the KLF10 gene is able to inhibit human
pancreatic cancer SW1990 cell proliferation and cause cell cycle arrest
at the G1-phase in vitro [8]. In our laboratory, we have further demon-
strated that KLF10 is able to up-regulate SEI-1 and subsequent p21 ex-
pression, which then affects subsequent cell cycle progression [9].
Unexpectedly, we have also observed the cell cycle-regulation of
KLF10 expression, with expression reaching its highest point prior to
the G1/S transition. Smurf-2, a Smad speciﬁc E3 ligase, is not only re-
sponsible for protein degradation through the ubiquitin-dependent
proteasome pathway, but also plays an important role in regulating
TGF-β signal transduction [10]. Similarly, KLF10 is degraded through in-
teraction with another ubiquitin E3 ligase, SIAH1 (seven-in-absentia
homologue 1) [11]. SIAH1 belongs to the RING domain family that
acts as a scaffolding protein and interactswith a variety of different sub-
strates that undergo ubiquitination and then degradation [12]. Based on
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late gene transcriptionmight be regulated by the proteasomal degrada-
tion of its downstream effector KLF10 through the SIAH mediated
pathway. Nonetheless, the mechanism by which KLF10 increase in G1
phase remains elusive.
Although a great deal of researchhas suggested an important role for
KLF10 in many biological processes, most of these studies have focused
on the transcriptional regulation of various genes and not on protein–
protein interactions and the molecular mechanisms involved. In this
study we have shown that CDK2 phosphorylates KLF10 at residue
Ser206 in vivo and in vitro. We have also found that a phospho-mimic
mutant of KLF10 preferentially dissociates from its E3 ligase (SIAH1)
when compared with its phospho-defective counterpart and that this
subsequently leads to a signiﬁcant increase in the level of KLF10. Our
ﬁndings suggest that the CDK2 phosphorylation-mediated KLF10 disso-
ciation from SIAH1 is linked to cell cycle progression. Taken together,
our previous and recent results indicate that the CDK2-dependent phos-
phorylation pathway plays a direct role in modulating the anti-
proliferation effects of TGF-β.
2. Material and methods
2.1. Cell culture
Human pancreatic carcinoma PANC-1 cells and human lung carcino-
ma H1299 cells were cultured in RPMI 1640 medium (Invitrogen) sup-
plemented with 10% fetal bovine serum (FBS, Biological Industries) at
37 °C in 5% CO2. Both cell lines were transfected using Lipofectamine
2000 according to the manufacturer’s instructions (Invitrogen). Cells
were harvested at 24 h post-transfection.
2.2. Protein preparation and quantiﬁcation
For Western blotting and immunoprecipitation, cell extracts were
prepared in lysis buffer (20 mM Tris–HCl, pH 8.0, 150 mM NaCl, 1%
Nonidet P-40, 1mMEDTA) containing 1× protease and phosphatase in-
hibitors (CompleteTM, PhosStopTM Roche). After sonication, cell extracts
were centrifuged at 12,000g for 10 min at 4 °C and the supernatants
were collected. The concentration of each preparation was determined
using a Pierce BCA protein assay kit and then the proteins were stored
at−80 °C until use.
2.3. Western blotting and co-immunoprecipitation
Cell extracts were prepared and subjected to SDS-PAGE analysis.
After separation, the proteins on the gel were transferred onto a PVDF
membrane. The blot was then incubated with blocking buffer (20 mM
Tris, 150 mM NaCl, 0.1% Tween20 and 5% non-fat milk) for 1 h at room
temperature and immunostained with antibodies as indicated. Protein
bands were detected by ECL reagent. For co-immunoprecipitation, cells
were transfected with plasmids using Lipofectamine 2000. Cell extracts
were incubatedwith antibodies for 1 h at 4 °Cwith rotation and followed
by incubating with 20 μl of protein G Sepharose (Millipore) for 4 h. The
Sepharose was then collected by centrifugation and washed with wash-
ing buffer (20 mM Tris–HCl, pH 8.0, 150 mM NaCl, 0.1% Nonidet P-40,
1mMEDTA) three times. The bound proteinswere analyzed byWestern
blotting using antibodies as indicated.
2.4. GST fusion proteins and pull-down assay
GST-tag KLF10 plasmids were transformed into Escherichia coli
BL21-CodonPlus® (DE3)-RIPL (Agilent) and then expression was in-
duced using 1 mM of isopropylthiogalactoside (IPTG) for 4 h at 37 °C.
The GST fusion proteinswere then puriﬁed according to standard proto-
cols. For the pull-down assays, equal amounts of GST and GST fusion
proteins were incubated for 3 h at 4 °C with cellular proteins from thevarious transfected cells as indicated. After incubation, the GST beads
were washed with buffer D (20 mM HEPES, pH 8.0, 20% glycerol,
100 mM KCl, and 0.2 mM EDTA, 0.5 mM PMSF, and 0.5 mM DTT)
three times. Finally, the bound proteins were released from the beads
directly using SDS sampling buffer and analyzed subsequently byWest-
ern blotting.
2.5. In vitro kinase assay
For the in vitro kinase assay, GST, GST-KLF10, GST-KLF10 (1–215),
GST-KLF10 (215–480), GST-KLF10 (120–270) and GST-KLF10 (120–
270) S206 were used as substrates. The substrates were combined
with recombinant CDK2/cyclinE1 in reaction buffer (25 mM Tris–HCl
pH 7.5, 5 mM β-glycerophosphate, 2 mM dithiothreitol, 0.1 mM
Na3VO4, 10 mMMgCl2, 30 μM ATP and 20 Ci γ33P-ATP) and incubated
at 30 °C for 30 min. The labeled proteins were then resolved by SDS-
PAGE and visualized by autoradiography.
2.6. Protein in-gel digestion
Speciﬁc protein bands on a 1D gel were manually excised from the
gel and cut into pieces. The gel pieces were rehydrated with 50 mM
DTE in 25mM ammoniumbicarbonate, pH 8.5, at 37 °C for 1 h, and sub-
sequently alkylated with 100mM iodoacetamide in 25mMammonium
bicarbonate, pH 8.5, at room temperature in dark for 1 h. The pieces
were thenwashed twicewith 50% acetonitrile in 25mMammoniumbi-
carbonate, pH8.5, for 15min each time, dehydratedwith acetonitrile for
5 min, dried, and rehydrated with a total of 100 ng of sequencing grade
Trypsin (Promega) in 25 mM ammonium bicarbonate, pH 8.5, at 37 °C
for 16 h. Following digestion, the tryptic peptides were extracted
twice with 50% acetonitrile containing 5% TFA for 3 min each time
with moderate sonication. Finally, the extracted solutions were pooled
and evaporated to dryness under vacuum.
2.7. LC-MS/MS
Tryptic digests were analyzed using nanoAcquity system (Waters)
coupled to an LTQ-Orbitrap XL (Thermo Fisher Scientiﬁc) mass spec-
trometer equipped with a nanoSpray source (Proxeon). For protein
identiﬁcation, mass spectra were acquired using the LTQ-Orbitrap pro-
grammed to perform FT scans (60,000 resolutions at m/z 400) over
the 350–1600 amu mass range with the top 10 ions from each scan se-
lected for LTQ-MS/MS. To improve the fragmentation spectra of the
phosphopeptides, “multistage activation” at 97.98, 48.99, 32.66, and
24.49 Thompson relative to the precursor ion was enabled for all MS/
MS events. The raw ﬁles were converted to peak lists in Mascot generic
format (MGF) ﬁles using RAW2MSM v. 1.10 software (Matthias Mann)
using default parameters and without any ﬁltering, charge state
deconvolution or deisotoping. The MGF ﬁles were then searched using
a Mascot 2.2 server against the Swissport human database (541,561 se-
quences; 192,480,382 residues).
2.8. Protein stability measurement
For the protein stability assays, exponentially growing H1299 cells
were transfected using Lipo2000 (Invitrogen) with plasmid HA-KLF10
or HA-KLF10S206D DNA expressing wild-type or S206D mutant. Cells
were treated with 100 μg/ml cycloheximide (Sigma) at 24 h post-
transfection and harvested at 0 (untreated) or indicated time points
after cycloheximide treatment. Cell extracts were prepared as described
above, which was followed by immunoblotting.
2.9. Plasmids and reagents
The construction of the KLF10 expression vectors has been described
previously[13]. Brieﬂy, the DNA fragments were ampliﬁed by
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Pharmingen) to generate Flag-KLF10, or into pcDNA3 (Invitrogen)
with a HA-tag to obtain HA-KLF10. HA-KLF10 (1–215 a.a.), HA-KLF10
(215–480 a.a.) and HA-KLF10 (1–356 a.a.) were obtained by inserting
DNA fragments encoding the corresponding length of amino acids
from the KLF10 into pcDNA3-HA plasmid. For bacterial expression,
KLF10 cDNA was inserted between the BamHI and EcoRI sites of
pGEX-5X-1(GE) to generate GST-KLF10. Similarly, GST-KLF10 (1–215
a.a.), GST-KLF10 (215–480 a.a.) and GST-KLF10 (120–270 a.a.) were
cloned into pGEX-5X-1 using DNA fragments encoding the correspond-
ing peptides fromKLF10. In addition, in order to generate the S206A and
S206Dmutants, residue Ser206 of KLF10was replaced with Ala andwith
Asp. The nucleotide substitutions were TCA N GCA (S206A) and
TCA N GAC (S206D). Both the mutant constructs of KLF10 were created
by PCR mutagenesis and were veriﬁed by DNA sequencing.
For CDK and cyclin expression, CDK2 and CDK4DNA fragmentswere
cloned into the EcoRI and BamHI sites of pRK5. The kinase inactive mu-
tants, pRK5-CDK2 D145N and pRK5-CDK2 T160A, were generated by
PCR-based mutagenesis. The nucleotide substitutions were GAC N AAC
(D145N) and ACC N GCC (T160A). HA-Cyclin A2 and HA-Cyclin D1
were cloned by inserting intact Cyclin A2 and Cyclin D1 into the
BamHI and XhoI sites of pcDNA3with a HA tag. TheDNA sequences cor-
responding to Cyclin D2, D3 and E1were cloned into the EcoRI and XhoI
sites of pcDNA3 to obtain HA-CyclinD2, HA-CyclinD3 and HA-Cyclin E1.
The DNA sequence of SIAH1was inserted into the EcoRI and SalI sites of
pRK5 to generate pRK5-SIAH1, and into the EcoRI and HindIII sites of
pCMV-Tag2A to obtain pCMVTag-SIAH1. pRK5-SIAH1 SBD was cloned
by inserting theDNA sequence of SIAH1SBD (substrate binding domain,
121–314 a.a.) into pRK5. All the plasmids described abovewere veriﬁed
by DNA sequencing.
α-KLF10 antibody was supplied by LTK BioLaboratories (Taiwan); it
is a mouse monoclonal antibody raised against amino acids 1–215 that
map within an internal region of human origin KLF10. The α-HA was
purchased from Roche. α-FlagM2 was obtained from Sigma. α-
Tubulin was bought from Neomarker. The Cyclin E and normal mouse
IgG antibodies were purchased from Millipore. α-Cdc2/CDK1 was
bought from Calbiochem. α-CDK2, α-CDK4, α-CDK6 and α-SIAH1
were all obtained from Santa Cruze.
Roscovitine and EDTA were bought from Sigma. The radioisotope
γ33P-ATP was obtained from Perkin Elmer. Recombinant kinase CDK2/
cyclin E was obtained from Millipore. CIAP (NEB). Okadaic
acid (Roche) and GST glutathione beads (GE) were also obtained
commercially.Fig. 1. KLF10 is a CDK2 associated protein. (A) KLF10 does not interactwith CDK1, CDK4 andCDK
prepared and subjected to immunoprecipitation (IP) byα-Flag antibody. The proteins from the
sociated proteins. Speciﬁc antibodies (α-CDK1, α-CDK4 and α-CDK6) were used in the Wester
were performedwith cell extracts of H1299 using either control IgG orα-KLF10 antibodies. Pre
cyclin E antibodies.3. Results
3.1. KLF10 is a CDK2 interacting protein in cells and is phosphorylated by
CDK2
We have previously demonstrated that KLF10 is phosphorylated in
human cells in vivo. Furthermore, a Raf-1 speciﬁcally directed phos-
phorylation of KLF10 and that this, subsequent to Pin1 isomerization,
together regulates KLF10 activity during tumor progression [14]. Using
a computation prediction program (PhosphoMotif), we tentatively
identiﬁed that KLF10 ought to be phosphorylated at Ser206 by CDK1,
CDK2, CDK4 and/or CDK6 (Supplemental Table 1). In addition, the con-
sensus phosphorylation motif at Ser206 for CDKs is completely con-
served between mouse and human. We next investigated the physical
association between KLF10 and CDKs using co-immunoprecipitation as-
says and speciﬁc CDK antibodies that are able to detect presence of CDK
in an immunoprecipitated KLF10 protein complex. The results are
shown in Fig. 1 and reveal that a complex is formed between KLF10
and CDK2 (Fig. 1B) but that complex formation does not occur with
CDK1, CDK4 and CDK6 (Fig. 1A). This implies that a speciﬁc CDK2-
dependent phosphorylation of KLF10 may exist. The cyclin-CDK com-
plex has been shown to be required for relevant substrate phosphoryla-
tion [15]. Using this approach, we designed studies to investigate the
protein interactions and then the phosphorylation. The association be-
tween KLF10 and CDK2, as well as between, KLF10 and CDK4 (as a neg-
ative control), and between KLF10 and various other cyclins (A2, E1, D1,
D2 and D3), were studied by GST-pull down assays. As demonstrated in
Fig. 2A, GST-KLF10was only able to pull-downCDK2 protein. To identify
whether KLF10 recruits cyclin E1 following CDK2 association,whole cell
extracts collected from cells transfected with HA-KLF10, Flag-CDK2 and
Flag-cyclin E1 were analyzed by co-immunoprecipitation and Western
blotting (Fig. 2B). The results showed that cyclin E1 was not readily
co-precipitatedwith KLF10 (Lane 9); however, co-precipitationwas de-
tected when CDK2was used as a bridge (lane 3 and 6). Thus our results
demonstrate that KLF10 is a CDK2-interacting protein both in vitro and
in vivo.
The phosphorylation of KLF10 by CDK2 was then examined in
kinase-transfected cells by Western blotting. The results are shown
in Fig. 2C and it was found that KLF10 was only phosphorylated by
the CDK2/cyclin E1 complex but not in presence of A2, D1, D2 or
D3, as demonstrated by the association studies. We next constructed
two “kinase-dead” mutants of the fusion gene in which the Cdk2 ki-
nase domain was inactivated, these were the D145N [16] and T160A6. H1299 cellswere transfectedwith Flag-KLF10. After 24 h transfection, cell extractswere
immunoprecipitation were separated and analyzed byWestern blotting to detect the as-
n blot as indicated. (B) KLF10 interacts with endogenous CDK2. Co-immunoprecipitations
cipitateswere recognized by KLF10 and the associationwas detected usingα-CDK2 andα-
Fig. 2. CDK2 interacts with KLF10 in vitro and in vivo. (A) The in vitro association of CDK2with KLF10was analyzed by GST pull down. Flag-tag CDKs or HA-tag cyclin was transfected into
H1299 cells individually. After 24 h of transfection, cell extracts were puriﬁed and incubatedwith GST or GST-KLF10 coupled to GSH-Sepharose. Proteins retained on Sepharose were then
subjected to Western blotting by using α-Flag or α-HA antibodies. (B) KLF10/CDK2/Cyclin E1 forms a complex in vivo. Flag-KLF10, HA-CDK2 and Flag-cyclin E1 plasmids were co-
transfected into H1299 cells. After 24 h of transfection, cell extracts were prepared and subjected to immunoprecipitation (IP) using control IgG and other antibodies as indicated. The
proteins from the immunoprecipitation were resolved and analyzed by α-Flag or α-HA antibodies to detect the associated proteins. (C) CDK2/cyclinE1 speciﬁcally phosphorylates
KLF10. Flag-CDKs and HA-cyclins plasmids were co-transfected into H1299 cells as indicated. After 24 h of transfection, cell extracts were prepared andWestern blotting was performed
using α-KLF10, α-Flag and α-HA antibodies. Equal amounts of proteins were loaded as indicated by detection of tubulin, which acts as an internal control. (D) CDK2 kinase activity is re-
quired for KLF10 phosphorylation. The wild type Flag-CDK2 and two kinase inactive mutants D145N and T160Awere introduced independently into H1299 cells with HA-cyclinE1 as in-
dicated. After 24 h of transfection, cell extracts were prepared and Western blotting was performed. Proteins were detected using α-KLF10, α-HA and α-Flag antibodies.
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the wild or mutant constructs in the presence or absence of
overexpressed HA-cyclin E1 were analyzed by immunoblotting to
determine the phosphorylated status of KLF10, and to examine the
role of the cyclin E1 in this process (Fig. 2D). The up shifted KLF10
is signiﬁcantly decreased in the CDK2 mutant (D145N and T160A)transfected cells when compared with those transfected with wild–
type (WT) KLF10 (compare Lane 6 with Lanes 7 and 8). Cells
transfected with CDK2 alone and without cyclin E1 did not show
these differences. Collectively, the results consistently demonstrate
that the CDK2/cyclin E1 complex regulates the phosphorylation of
KLF10 through an intracellular association.
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KLF10, an in vitro kinase assay was performed using either GST alone or
the GST-KLF10 fusion protein as the substrate and the active recombi-
nant CDK2/cyclin E1 as the kinase; the reaction was carried out in the
presence of radiolabeled [γ-33P] ATP as a phosphate donor. CDK2/cyclin
E1 activity targeting KLF10 should result in the incorporation of
radiolabeled phosphate into the KLF10 protein. Incubation of recombi-
nant GST-KLF10 protein with CDK2/cyclin E1 revealed the presence ofFig. 3. CDK2 phosphorylates KLF10 at Ser206. (A) CDK2 phosphorylates KLF10 primarily at the
recombinant CDK2/cyclin E and the following substrates: GST, GST-KLF10 (1–480 a.a.), GST-KLF
were resolved by SDS-PAGE and visualized by autoradiography. Lower panel: The protein subst
assaywas conductedusing theGST-KLF10 (120–270 a.a.) region fromeither awild type (WT) pr
were quantiﬁed and the relative level of themutant compared to that of the wild type substrate
from the GST-KLF10 protein that has been phosphorylated. The product ion y4, which carries a p
are indicated with p. “b” and “y” ion series represent fragment ions containing the N- and C-tea phosphorylated GST-KLF10 (1–480 a. a.) band at about 72 kDa
(Fig. 3A, lane 4); this band was absent when CDK2/cyclin E1 was not
added (lane 3) and alsowas not presentwhenGST proteinwas incubat-
edwith CDK2/cyclin E1 (Fig. 3A, lanes 1 and 2). Similar resultswere also
obtained using the GST-KLF10 1–215 a.a. and 215–480 a.a. deletion fu-
sion proteins. CDK2 and other CDKs often recognize and phosphorylate
a serine, a threonine or a proline in that order of preference. According
to the phosphorylation predicated program, only one such siteN-terminal in vitro. Upper panel: The in vitro kinase assay was performed using 7.5 ng of
10 (1–215 a.a.) and GST-KLF10 (215–480 a.a.). After 30min reactions, the labeled proteins
rates used in reaction were detected by Coomassie blue staining. (B) CDK2/cyclin E kinase
otein or amino acid substitutionmutant (S206A). Phosphorylation levels of both substrates
. (C) MS/MS spectrum of the [M+ 2H]2+ (m/z 639.79) ion of the peptide NIPCAAVpSPNR
hosphate, indicates that Ser206 was phosphorylated. Residues bearing phosphate moieties
rmini of the peptide, respectively.
Fig. 5. Phosphorylation of KLF10 Ser206 abolishes binding of SIAH1 to KLF10. (A) SIAH1
does not bind to phosphorylated KLF10. Upper panel: H1299 cells were transfected with
or without Flag-SIAH1. After 24 h of transfection, cell extracts were prepared and subject-
ed to GST-pull down using GST-KLF10 S206A or S206D. After incubation, bound proteins
were resolved by SDS-PAGE and Western blotting carried out by α-SIAH1 antibody.
Lower panel: the GST proteins used in the assay are identiﬁed by Coomassie blue staining.
(B) Flag-SIAH1 was replaced by the substrate binding domain only (Flag-SIAH1 SBD) in
the GST pull down assay. After interaction, bound proteins were detected using α-Flag
antibodies.
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phosphorylate KLF10 at Ser206, we repeated the in vitro kinase assays
in the presence of radiolabeled [γ-33P] ATP. The phosphorylated signal
was detected and quantiﬁed by autoradiography (Fig. 3B); a much
lower level of phosphorylation signal, almost one ﬁfth that of the con-
trol, was found when the Ser206 site was mutated. Finally, Ser206 phos-
phorylation of both endogenous and ectopically expressed KLF10 in
H1299 cells was conﬁrmed by mass spectrometry analysis. As shown
in Fig. 3C, a phosphorylated peptide from GST-KLF10 protein was iden-
tiﬁed as NIPCAAVpSPNR due to the presence of the observed ion y4,
which carries a phosphate. The results conﬁrm that the phosphorylation
occurs at Ser206. Taking the above results together, our ﬁndings show
that CDK2/cyclin E1 phosphorylates Ser206 of KLF10 both in vitro and
in vivo.
3.2. CDK2 phosphorylation stabilizes KLF10 by competing with E3 ligase
Previous results have indicated that the stability of KLF10 protein is
regulated by interaction with the human homologue of Seven in Absentia
(SIAH1), which then modulates the activity of the TGF-β signal transduc-
tion pathway [11]. In addition, it is suggested by our results as shown in
Fig. 1B that phosphorylated KLF10 seems to be more stable. Based on
these ﬁndings, we next investigatedwhether CDK2-dependent phosphor-
ylation is capable of stabilizing KLF10. We co-transfected cells with or
without CDK2 and cyclin E1 and then detected the level of endogenous
KLF10. The results are presented in Fig. 4A, CDK2 phosphorylation-
dependent association with KLF10 was found to affect KLF10 stability. To
conﬁrm that the phosphorylation and stabilization of KLF10 is dependent
on CDK2 kinase activity,we treated the cellswith the CDKkinase inhibitor,
roscovitine (Fig. 4B). Roscovitine treatment decreased the phosphorylated
status of KLF10, which is consistent with a previous report [18]. Interest-
ingly, however, roscovitine effectively attenuated the expression level of
KLF10.Moreover, the phospho-mimicmutant S206D (D: aspartic acid) in-
creases the amount of KLF10 present when compared with the phospho-
defective mutant Ser206A (A: Alanine) (Fig. 4C). We next hypothesized
that Ser206 phosphorylation may interfere with the association of SIAH1,
which binds to a site near the CDK2 phosphorylated site. To prove this,
GST-pull-down assays were repeated using a phosphorylation-mimic
mutant KLF10-S206D. The results showed a signiﬁcant reduction in
the association with SIAH1 (Fig. 5A) and SIAH1 SBD (substrate binding
domain; Fig. 5B) when compared with non-phosphorylated KLF10
(S206A). Furthermore, to speciﬁcally explore protein stability, cellular
levels of wild type KLF10 and S206D KLF10 were measured after the
cells were co-transfected with various doses of SIAH1. As shown in
Fig. 6, S206D KLF10 is much less degradable by SIAH1 than wild typeFig. 4. CDK2 phosphorylates KLF10 and increases its protein stability. (A) CDK2 cyclin E1 stabil
alone or together as indicated. After 24 h of transfection, cell extracts were prepared and prote
endogenous CDK2 activity decreases the protein stability of KLF10. HA-tag full-length (1–4
transfected into H1299 cells. At 24 h after transfection, the cells were treated with roscovitine (
tibody. (C) Substitution of Ser206 to alanine or aspartic acid alters the protein stability of KLF1
transfected into H1299 cells. After 24 h of transfection, cell extracts were prepared and KLF10
by detection of tubulin.KLF10. Moreover, the cycloheximide shut off assay was adopted to fur-
ther conﬁrm this correlation (Supplemental Fig. 1). Finally, these ﬁnd-
ings conﬁrm the essential role of S206 phosphorylation in the
regulation of KLF10 stability.
4. Discussion
The mechanism of TGF-β1-mediated growth arrest at G1 phase in
epithelial cells includes the lowering of the levels of expression of cyclin
D, E and A, a reduction in Cdk4 synthesis, a downregulation of c-myc,
and various other effects [19–21]. Furthermore, various Cdk inhibitors,
namely p15INK4, p21 CIP1, and p27KIP1, have been shown to be potential
cellular mediators in TGF-β1-mediated cell cycle G1 arrest [20,22]. In-
terestingly, most of the genetic changes observed in cancer cells involve
genes that control G1 cell cycle progression. Previous studies have re-
vealed that there are speciﬁc signals controlling G1 cell cycle progres-
sion that need to be dysregulated during tumorigenesis. However, the
speciﬁc targets or signals involved and their related pathways have
not as yet been identiﬁed.
TGF-β1 regulates and increases the intracellular levels of KLF10 and,
furthermore, the anti-proliferative role and apoptotic effects of KLF10
have been conﬁrmed. Moreover, it has recently been reported thatizes KLF10. Flag-CDK2 and HA-cyclin E1 plasmids were transfected into H1299 cells either
in expression was detected using α-KLF10, α-Flag and α- HA antibodies. (B) Inhibition of
80 a.a.) and a series of KLF10 deletion mutants (1–356, 1–215 and 215–480 a.a.) were
20 μM) for 6 h. Cell extracts were then subjected to Western blot analysis using α-HA an-
0. HA-KLF10, HA-KLF10 S206A and the phosphor-mimic mutant HA-KLF10 S206D were
was detected using α-HA antibodies. Equal amounts of proteins were loaded as indicated
Fig. 6. Phosphorylation of KLF10 Ser206 attenuates SIAH1-induced KLF10 degradation. H1299 cells were transfected with HA-KLF10 and the indicated amounts of Flag-SIAH1 expression
vectors. The total amount ofDNAwas kept constant by adding pCMVtag2 (Flag-) vector. Cell extractswerepuriﬁed24h after transfection and the proteins presentwere analyzed byWest-
ern blotting using either α-HA or α-Flag antibodies.
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which results in the induction of cell cycle arrest [23,24]. The authors
further suggested that KLF10might regulate the expression of genes in-
volving cell cycle regulation. It has been found that KLF10 dose-
dependently activates p21CIP1 transcription, and this is independent of
the p53 and Sp1 binding sites in the p21CIP1 promoter [25].We have fur-
ther provided evidence that KLF10 is able tomodulate the transcription-
al activation of SEI-1 and that over-expression of SEI-1 causes the
amount of p21CIP1 in cells to be increased [9]. These results prompted
us to propose that CDK2 phosphorylates the KLF10,which prolongs pro-
tein stability and thus directly increases the level of p21CIP1 during the
cell cycle.
In several types of human carcinomas, mutations or loss of hetero-
zygosity (LOH) in key components of the TGF-β pathway has been ob-
served [26,27]. Along the pathway, KLF10 has been reported to be
down-regulated in human cancers; these include malignant prostate
cancer, malignant breast cancer and brain tumors [25]. Our previous
results have also shown that there is loss of KLF10 during pancreatic
carcinogenesis [28]. All these ﬁndings point to an important role for
KLF10 in various cancers. Most KLF10 related studies have focused
on the transcriptional regulation of various genes, but information on
post-translational modiﬁcation is still lacking. Post-translational mod-
iﬁcations offer a dynamic way of regulating protein activity, subcellu-
lar localization, stability, etc. Indeed, adding or removing a dianionic
phosphate group somewhere on a protein is likely to change its
physico-chemical properties, stability, kinetics, and dynamics. Recent-
ly, using the yeast two-hybrid system, we have identiﬁed peptidyl-
prolyl cis–trans isomerase NIMA-interacting 1 (PIN1) as a candidate
protein for interaction with KLF10 [14]. Through protein–protein in-
teraction assays, we have shown that the Pro-directed Ser/Thr-Pro
motif at Thr-93 in the KLF10 N-terminal region is essential for the in-
teraction between KLF10 and PIN1. More importantly, PIN1 interacts
with KLF10 in a phosphorylation-dependent manner and this interac-
tion promotes KLF10 protein degradation in cells. Taken all our results
together, phosphorylation and dephosphorylation of speciﬁc sites on
KLF10 occurs throughout the cell cycle process and thusmust be tight-
ly controlled.
SIAH1 is the member of the highly conserved SINA/SIAH family
that functions in E3 ubiquitin ligase complexes and facilitates the
ubiquitination anddegradation of awide range of cellular proteins. Sever-
al studies indicated that SIAH ubiquitin ligases facilitate substrate
ubiquitinylation and lead target proteins to the proteasomal degradation
pathway, includingACK1, CBP/p300, Tip60 andPCAF [29,30]. On the other
hand, cells lacking the Siah1a/Siah2 genes have more acetylated proteins
and functional assays have revealed that these modiﬁcations play an im-
portant role in cell cycle regulation [31,32]. House et al. [33] identiﬁed a
peptide motif (PxAxVxP) that mediates the interaction of SIAH protein
with a range of protein partners. This SIAH1 binding motif has been
found in various interacting proteins, such as SIP, OBF-1, DCC, NUMB,
EF1-δ, Vav, Kid, N-CoR, FIR and others. KLF10 also is one of SIAH’spotential substrates because of the presence of an appropriate domain lo-
cated from 193 to 215 a.a. (VEAARKNIPCAAVSPNRSKCERN; the
underlining indicates a SIAH1 binding motif, while the gray and bold
character indicates the CDK2 phosphorelated site). Notably, this stretch
contains a serine residue that is immediately followed by a proline resi-
due. This motif is also recognized by CDK2, as shown by the disappear-
ance of phosphopeptide upon mutation of S206. A close examination of
this sequence indicated that, as well as the Ser206 site being present in
this region, the sequence also strictly fulﬁls the requirements for recogni-
tion by CDK2 (Fig. 5). This may be accounted for by improper folding of
the C-terminus of KLF10, whichmay in turn limit access to the target site.
Since Cdk has numerous substrates in eukaryotic cells and modify
these substrates at multiple sites, it is reasonable to assume there is
competition among these substrates in terms of catalytic modiﬁcation.
In this study, we have shown that KLF10 protein has tightly controlled
expression and that the expression level varies in a cell cycle-
dependent manner whereby CDK2 up-regulates the protein level of
KLF10 through interference with the protein's association with SIAH1.
The KLF10-mediated pathway through p21CIP1 might be essentially to
the cell cycle control and even to apoptosis. Since the stability of
KLF10 is effectively modulated by posttranslational modiﬁcations, our
observations conﬁrm the presence of two opposing stabilizing effects,
namely via Raf-1 [14] and via CDK2 (in this study). The phosphorylation
mechanism also highlights the presence of various interesting mecha-
nisms that are associated with the regulation of KLF10 during cell
cycle progression. Crosstalk between these two scenarios related to
the stability of KLF10 is likely to provide novel viewpoints when study-
ing TGF-β1 during carcinoma initiation.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2015.02.018.Transparency document
The Transparency document associated with this article can be
found, in the online version.Acknowledgments
The study was partially supported by grants TMU101-AE1-B27, NSC
101-2628-B-038-002-MY2 (VHSC) and NSC 101-2628-B-400-001-MY2
(WCYY) from the Taipei Medical University and National Science Coun-
cil, Taipei, Taiwan.References
[1] C.E. Wenner, S. Yan, Biphasic role of TGF-beta1 in signal transduction and crosstalk,
J. Cell. Physiol. 196 (2003) 42–50.
[2] G.J. Hannon, D. Beach, p15INK4B is a potential effector of TGF-beta-induced cell
cycle arrest, Nature 371 (1994) 257–261.
1181C.-H. Lin et al. / Biochimica et Biophysica Acta 1853 (2015) 1174–1181[3] M.B. Datto, Y. Li, J.F. Panus, D.J. Howe, Y. Xiong, X.F. Wang, Transforming growth fac-
tor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-
independent mechanism, Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 5545–5549.
[4] K. Polyak, J.Y. Kato, M.J. Solomon, C.J. Sherr, J. Massague, J.M. Roberts, A. Koff,
p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact
inhibition to cell cycle arrest, Genes Dev. 8 (1994) 9–22.
[5] M. Kretzschmar, Transforming growth factor-beta and breast cancer: transforming
growth factor-beta/SMAD signaling defects and cancer, Breast Cancer Res. 2
(2000) 107–115.
[6] A. Moustakas, K. Pardali, A. Gaal, C.H. Heldin, Mechanisms of TGF-beta signaling in
regulation of cell growth and differentiation, Immunol. Lett. 82 (2002) 85–91.
[7] S.J. Kim, J. Letterio, Transforming growth factor-beta signaling in normal and malig-
nant hematopoiesis, Leukemia 17 (2003) 1731–1737.
[8] L. Jiang, F. Wang, F. Lin, S.M. Gao, Y. Tan, Y. Han, C. Chen, J. Wu, Lentivirus-mediated
overexpression of TGF-beta inducible early gene 1 inhibits SW1990 pancreatic can-
cer cell growth, Cell Biol. Int. 35 (2011) 891–896.
[9] Min-Ju Wu, Hsuen-Wen Chang, Yong-Tzuo Lai, Ching-Hui Lin, Winston C.Y. Yu,
Vincent H.S. Chang, KLF10 affects pancreatic function via the SEI-1/p21Cip1 path-
way, Int. J. Biochem. Cell Biol. 60 (2015) 53–59.
[10] X. Lin, M. Liang, X.H. Feng, Smurf2 is a ubiquitin E3 ligase mediating proteasome-
dependent degradation of Smad2 in transforming growth factor-beta signaling, J.
Biol. Chem. 275 (2000) 36818–36822.
[11] S.A. Johnsen, M. Subramaniam, D.G. Monroe, R. Janknecht, T.C. Spelsberg, Modula-
tion of transforming growth factor beta (TGFbeta)/Smad transcriptional responses
through targeted degradation of TGFbeta-inducible early gene-1 by human seven
in absentia homologue, J. Biol. Chem. 277 (2002) 30754–30759.
[12] V. Rimsa, T.C. Eadsforth, W.N. Hunter, Two high-resolution structures of the human
E3 ubiquitin ligase Siah1, Acta Crystallogr. Sect. F: Struct. Biol. Cryst. Commun. 69
(2013) 1339–1343.
[13] H.S. Chang, C.H. Lin, C.H. Yang, Y.J. Liang, W.C. Yu, The human papillomavirus-16
(HPV-16) oncoprotein E7 conjugates with and mediates the role of the
transforming growth factor-beta inducible early gene 1 (TIEG1) in apoptosis, Int. J.
Biochem. Cell Biol. 42 (2010) 1831–1839.
[14] Y.C. Hwang, C.H. Yang, C.H. Lin, H.J. Ch'ang, V.H. Chang, W.C. Yu, Destabilization of
KLF10, a tumor suppressor, relies on thr93 phosphorylation and isomerase associa-
tion, Biochim. Biophys. Acta 1833 (2013) 3035–3045.
[15] D. Parry, S. Bates, D.J. Mann, G. Peters, Lack of cyclin D-Cdk complexes in Rb-
negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor
gene product, EMBO J. 14 (1995) 503–511.
[16] B.A. Cohen, P. Colas, R. Brent, An artiﬁcial cell-cycle inhibitor isolated from a combi-
natorial library, Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 14272–14277.
[17] S. Maddika, S.R. Ande, E. Wiechec, L.L. Hansen, S. Wesselborg, M. Los, Akt-mediated
phosphorylation of CDK2 regulates its dual role in cell cycle progression and apopto-
sis, J. Cell Sci. 121 (2008) 979–988.
[18] S. Bach, M. Knockaert, J. Reinhardt, O. Lozach, S. Schmitt, B. Baratte, M. Koken, S.P.
Coburn, L. Tang, T. Jiang, D.C. Liang, H. Galons, J.F. Dierick, L.A. Pinna, F. Meggio, F.
Totzke, C. Schachtele, A.S. Lerman, A. Carnero, Y. Wan, N. Gray, L. Meijer, Roscovitinetargets, protein kinases and pyridoxal kinase, J. Biol. Chem. 280 (2005)
31208–31219.
[19] P. Mukherjee, S.L. Winter, M.G. Alexandrow, Cell cycle arrest by transforming
growth factor beta1 near G1/S is mediated by acute abrogation of prereplication
complex activation involving an Rb-MCM interaction, Mol. Cell. Biol. 30 (2010)
845–856.
[20] F. Zhang, M. Monkkonen, S. Roth, M. Laiho, TGF-beta induced G(1) cell cycle arrest
requires the activity of the proteasome pathway, Transform. Growth Factor Exp.
Cell Res. 281 (2002) 190–196.
[21] S.G. Kim, S.N. Kim, H.S. Jong, N.K. Kim, S.H. Hong, S.J. Kim, Y.J. Bang, Caspase-mediated
Cdk2 activation is a critical step to execute transforming growth factor-beta1-induced
apoptosis in human gastric cancer cells, Oncogene 20 (2001) 1254–1265.
[22] S. Ciarallo, V. Subramaniam,W. Hung, J.H. Lee, R. Kotchetkov, C. Sandhu, A. Milic, J.M.
Slingerland, Altered p27(Kip1) phosphorylation, localization, and function in
human epithelial cells resistant to transforming growth factor beta-mediated
G(1) arrest, Mol. Cell. Biol. 22 (2002) 2993–3002.
[23] R. Alvarez-Rodriguez, M. Barzi, J. Berenguer, S. Pons, Bone morphogenetic protein 2
opposes Shh-mediated proliferation in cerebellar granule cells through a TIEG-1-
based regulation of Nmyc, J. Biol. Chem. 282 (2007) 37170–37180.
[24] G. Spittau, N. Happel, M. Behrendt, T.I. Chao, K. Krieglstein, B. Spittau, Tieg1/Klf10 is
upregulated by NGF and attenuates cell cycle progression in the pheochromocyto-
ma cell line PC12, J. Neurosci. Res. 88 (2010) 2017–2025.
[25] K.D. Song, D.J. Kim, J.E. Lee, C.H. Yun, W.K. Lee, KLF10, transforming growth factor-
beta-inducible early gene 1, acts as a tumor suppressor, Biochem. Biophys. Res.
Commun. 419 (2012) 388–394.
[26] E. Meulmeester, P. Ten Dijke, The dynamic roles of TGF-beta in cancer, J. Pathol. 223
(2011) 205–218.
[27] L. Levy, C.S. Hill, Alterations in components of the TGF-beta superfamily signaling
pathways in human cancer, Cytokine Growth Factor Rev. 17 (2006) 41–58.
[28] V.H. Chang, P.Y. Chu, S.L. Peng, T.L. Mao, Y.S. Shan, C.F. Hsu, C.Y. Lin, K.K. Tsai, W.C.
Yu, H.J. Ch'ang, Kruppel-like factor 10 expression as a prognostic indicator for pan-
creatic adenocarcinoma, Am. J. Pathol. 181 (2012) 423–430.
[29] M. Buchwald, K. Pietschmann, P. Brand, A. Gunther, N.P. Mahajan, T. Heinzel, O.H.
Kramer, SIAH ubiquitin ligases target the nonreceptor tyrosine kinase ACK1 for
ubiquitinylation and proteasomal degradation, Oncogene 32 (2013) 4913–4920.
[30] I. Grishina, K. Debus, C. Garcia-Limones, C. Schneider, A. Shresta, C. Garcia, M.A.
Calzado, M.L. Schmitz, SIAH-mediated ubiquitination and degradation of acetyl-
transferases regulate the p53 response and protein acetylation, Biochim. Biophys.
Acta 1823 (2012) 2287–2296.
[31] T. Tanaka, M. Iino, Sec6 regulated cytoplasmic translocation and degradation of p27
via interactions with Jab1 and Siah1, Cell. Signal. 26 (2014) 2071–2085.
[32] Y. Nagano, T. Fukushima, K. Okemoto, K. Tanaka, D.D. Bowtell, Z. Ronai, J.C. Reed, S.
Matsuzawa, Siah1/SIP regulates p27(kip1) stability and cell migration under meta-
bolic stress, Cell Cycle 10 (2011) 2592–2602.
[33] C.M. House, I.J. Frew, H.L. Huang, G. Wiche, N. Traﬁcante, E. Nice, B. Catimel, D.D.
Bowtell, A binding motif for Siah ubiquitin ligase, Proc. Natl. Acad. Sci. U. S. A. 100
(2003) 3101–3106.
